Skip to main content
Erschienen in: Drugs 11/2013

01.07.2013 | Adis Drug Evaluation

Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years

verfasst von: Gillian M. Keating

Erschienen in: Drugs | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

The live, attenuated shingles (herpes zoster) vaccine Zostavax® is approved in the EU for use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. In adults aged ≥60 years, zoster vaccine reduced the burden of illness associated with herpes zoster, with reductions in the incidence of postherpetic neuralgia and herpes zoster, according to the results of the Shingles Prevention Study. Results of subsequent Short- and Long-Term Persistence Substudies indicate that the efficacy of zoster vaccine is maintained in the longer term, albeit with a gradual decline over time. In the Zostavax Efficacy and Safety Trial, zoster vaccine reduced the incidence of herpes zoster in adults aged 50–59 years. Findings of these studies are supported by the results of large, retrospective, cohort studies. Zoster vaccine was generally well tolerated, with injection-site adverse events being the most commonly reported adverse events. In conclusion, zoster vaccine provides an important opportunity to reduce the burden of illness associated with herpes zoster by reducing the incidence of herpes zoster and postherpetic neuralgia.
Literatur
1.
Zurück zum Zitat Drolet M, Oxman MN, Levin MJ, et al. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013;9(5). Drolet M, Oxman MN, Levin MJ, et al. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013;9(5).
2.
Zurück zum Zitat Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Phys. 2011;83(12):1432–7. Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Phys. 2011;83(12):1432–7.
3.
Zurück zum Zitat Li H-T, Lu S, Liu J-M. Herpes zoster vaccination in people aged 50–59 years. Clin Infect Dis. 2012;54(7):929–30.CrossRefPubMed Li H-T, Lu S, Liu J-M. Herpes zoster vaccination in people aged 50–59 years. Clin Infect Dis. 2012;54(7):929–30.CrossRefPubMed
4.
Zurück zum Zitat Pinchinat S, Cebrián-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13(1):170.CrossRefPubMed Pinchinat S, Cebrián-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13(1):170.CrossRefPubMed
5.
Zurück zum Zitat Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.CrossRefPubMed Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.CrossRefPubMed
6.
Zurück zum Zitat Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417–42.CrossRefPubMed Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417–42.CrossRefPubMed
7.
Zurück zum Zitat Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging. 2008;25(12):991–1006.CrossRefPubMed Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging. 2008;25(12):991–1006.CrossRefPubMed
10.
Zurück zum Zitat Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol. 2008;15(2):314–9.CrossRefPubMed Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol. 2008;15(2):314–9.CrossRefPubMed
11.
Zurück zum Zitat Sanford M, Keating GM. Zoster vaccine (Zostavax®): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159–76.CrossRefPubMed Sanford M, Keating GM. Zoster vaccine (Zostavax®): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159–76.CrossRefPubMed
12.
Zurück zum Zitat Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–8.CrossRefPubMed Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–8.CrossRefPubMed
13.
Zurück zum Zitat Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–35.CrossRefPubMed Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–35.CrossRefPubMed
14.
Zurück zum Zitat Levin MJ, Schmader KE, Zerbe GO, et al. Safety, tolerability, and immunogenicity of a booster dose of zoster vaccine (ZV) administered ≥10 years after a first dose compared with a first dose of ZV [abstract]. 20th IAGG World Congress of Gerontology and Geriatrics; 23–27 Jun 2013; Seoul. Levin MJ, Schmader KE, Zerbe GO, et al. Safety, tolerability, and immunogenicity of a booster dose of zoster vaccine (ZV) administered ≥10 years after a first dose compared with a first dose of ZV [abstract]. 20th IAGG World Congress of Gerontology and Geriatrics; 23–27 Jun 2013; Seoul.
16.
Zurück zum Zitat Parrino J, Marquez F, Fisher CL, et al. Safety, tolerability, and immunogenicity of zoster vaccine in patients on chronic/maintenance corticosteroids [abstract]. Arthritis Rheum. 2011;63(Suppl 10):2071. Parrino J, Marquez F, Fisher CL, et al. Safety, tolerability, and immunogenicity of zoster vaccine in patients on chronic/maintenance corticosteroids [abstract]. Arthritis Rheum. 2011;63(Suppl 10):2071.
17.
Zurück zum Zitat Wasan S, Berg A, Liang YM, et al. Immune response and safety of herpes zoster vaccine in IBD patients on methotrexate or thiopurines [abstract no. 1651]. Am J Gastroenterol. 2012;107(Suppl 1):S668. Wasan S, Berg A, Liang YM, et al. Immune response and safety of herpes zoster vaccine in IBD patients on methotrexate or thiopurines [abstract no. 1651]. Am J Gastroenterol. 2012;107(Suppl 1):S668.
18.
Zurück zum Zitat Benson C, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV + adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo- controlled trial [abstract no. 96]. 19th Conference on Retroviruses and Opportunistic Infections; 5–8 Mar 2012; Seattle (WA). Benson C, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV + adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo- controlled trial [abstract no. 96]. 19th Conference on Retroviruses and Opportunistic Infections; 5–8 Mar 2012; Seattle (WA).
20.
Zurück zum Zitat Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200(7):1068–77.CrossRefPubMed Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200(7):1068–77.CrossRefPubMed
21.
Zurück zum Zitat Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis. 2013;56(8):1085–93.CrossRefPubMed Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis. 2013;56(8):1085–93.CrossRefPubMed
22.
Zurück zum Zitat Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010;28(25):4204–9.CrossRefPubMed Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010;28(25):4204–9.CrossRefPubMed
23.
Zurück zum Zitat Arnou R, Fiquet A, Thomas S, et al. Immunogenicity and safety of Zostavax® approaching expiry potency in individuals aged ≥50 years. Hum Vaccin. 2011;7(10):1060–5.CrossRefPubMed Arnou R, Fiquet A, Thomas S, et al. Immunogenicity and safety of Zostavax® approaching expiry potency in individuals aged ≥50 years. Hum Vaccin. 2011;7(10):1060–5.CrossRefPubMed
24.
Zurück zum Zitat Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55(10):1499–507.CrossRefPubMed Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55(10):1499–507.CrossRefPubMed
25.
Zurück zum Zitat Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 2012;30(5):904–10.CrossRefPubMed Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 2012;30(5):904–10.CrossRefPubMed
26.
Zurück zum Zitat MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin. 2010;6(11):894–902.CrossRefPubMed MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin. 2010;6(11):894–902.CrossRefPubMed
27.
Zurück zum Zitat Vesikari T, Hardt R, Rümke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥70 years: a randomized study of a single dose versus two different two-dose schedules. Hum Vaccin Immunother. 2013;9:4.CrossRef Vesikari T, Hardt R, Rümke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥70 years: a randomized study of a single dose versus two different two-dose schedules. Hum Vaccin Immunother. 2013;9:4.CrossRef
28.
Zurück zum Zitat Sutradhar SC, Wang WWB, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol. 2009;16(5):646–52.CrossRefPubMed Sutradhar SC, Wang WWB, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol. 2009;16(5):646–52.CrossRefPubMed
29.
Zurück zum Zitat Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed
30.
Zurück zum Zitat Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMed Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMed
31.
Zurück zum Zitat Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.CrossRefPubMed Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.CrossRefPubMed
32.
Zurück zum Zitat Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160–6.CrossRefPubMed Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160–6.CrossRefPubMed
33.
Zurück zum Zitat Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis. 2012;206(2):190–6.CrossRefPubMed Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis. 2012;206(2):190–6.CrossRefPubMed
34.
Zurück zum Zitat Tseng HF, Smith N, Sy LS, et al. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29(20):3628–32.CrossRefPubMed Tseng HF, Smith N, Sy LS, et al. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29(20):3628–32.CrossRefPubMed
35.
Zurück zum Zitat Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13(5):R174.CrossRefPubMed Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13(5):R174.CrossRefPubMed
36.
Zurück zum Zitat Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.CrossRefPubMed Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.CrossRefPubMed
37.
Zurück zum Zitat Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634–41.CrossRefPubMed Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634–41.CrossRefPubMed
39.
Zurück zum Zitat Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the Shingles Prevention Study: a randomized trial. Ann Intern Med. 2010;152(9):545–54.CrossRefPubMed Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the Shingles Prevention Study: a randomized trial. Ann Intern Med. 2010;152(9):545–54.CrossRefPubMed
40.
Zurück zum Zitat Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013;. doi:10.1093/infdis/jit182. Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013;. doi:10.​1093/​infdis/​jit182.
41.
Zurück zum Zitat Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin. 2011;7(11):1130–6.CrossRefPubMed Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin. 2011;7(11):1130–6.CrossRefPubMed
42.
Zurück zum Zitat Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 2012;271(5):510–20.CrossRefPubMed Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 2012;271(5):510–20.CrossRefPubMed
43.
Zurück zum Zitat Baxter R, Tran TN, Hansen J, et al. Safety of Zostavax™: a cohort study in a managed care organization. Vaccine. 2012;30(47):6636–41.CrossRefPubMed Baxter R, Tran TN, Hansen J, et al. Safety of Zostavax™: a cohort study in a managed care organization. Vaccine. 2012;30(47):6636–41.CrossRefPubMed
44.
Zurück zum Zitat Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.CrossRefPubMed Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.CrossRefPubMed
45.
Zurück zum Zitat Bilcke J, Marais C, Ogunjimi B, et al. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30(3):675–84.CrossRefPubMed Bilcke J, Marais C, Ogunjimi B, et al. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30(3):675–84.CrossRefPubMed
46.
Zurück zum Zitat van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67.CrossRefPubMed van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67.CrossRefPubMed
47.
Zurück zum Zitat Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Effect Resour Allocat. 2010;8(7). Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Effect Resour Allocat. 2010;8(7).
48.
Zurück zum Zitat van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.CrossRefPubMed van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.CrossRefPubMed
49.
Zurück zum Zitat de Boer PT, Pouwels KB, Cox JM, et al. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31(9):1276–83.CrossRefPubMed de Boer PT, Pouwels KB, Cox JM, et al. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31(9):1276–83.CrossRefPubMed
50.
Zurück zum Zitat Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749–56.CrossRefPubMed Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749–56.CrossRefPubMed
51.
Zurück zum Zitat Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.CrossRefPubMed Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.CrossRefPubMed
52.
Zurück zum Zitat Oxman MN, Gershon AA, Poland GA. Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection. Vaccine. 2011;29(20):3625–7.CrossRefPubMed Oxman MN, Gershon AA, Poland GA. Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection. Vaccine. 2011;29(20):3625–7.CrossRefPubMed
53.
Zurück zum Zitat Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656–66.PubMed Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656–66.PubMed
54.
Zurück zum Zitat White RR, Lenhart G, Singhal PK, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics. 2009;27(9):781–92.CrossRefPubMed White RR, Lenhart G, Singhal PK, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics. 2009;27(9):781–92.CrossRefPubMed
56.
Zurück zum Zitat Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.CrossRefPubMed Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.CrossRefPubMed
57.
Zurück zum Zitat Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J. 2010;182(16):1731–6.CrossRef Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J. 2010;182(16):1731–6.CrossRef
58.
Zurück zum Zitat Harpaz R, Nagel MA, Schmader K, et al. Roundtable on postherpetic neuralgia: what, why, how long, and what’s next? Popul Health Manag. 2012;15(6):385–90.CrossRefPubMed Harpaz R, Nagel MA, Schmader K, et al. Roundtable on postherpetic neuralgia: what, why, how long, and what’s next? Popul Health Manag. 2012;15(6):385–90.CrossRefPubMed
59.
Zurück zum Zitat Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.CrossRefPubMed Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.CrossRefPubMed
60.
Zurück zum Zitat Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38–47.CrossRefPubMed Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38–47.CrossRefPubMed
61.
Zurück zum Zitat Bilcke J, Ogunjimi B, Hulstaert F, et al. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine. 2012;30(17):2795–800.CrossRefPubMed Bilcke J, Ogunjimi B, Hulstaert F, et al. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine. 2012;30(17):2795–800.CrossRefPubMed
62.
Zurück zum Zitat Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269(5):496–506.CrossRefPubMed Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269(5):496–506.CrossRefPubMed
63.
Zurück zum Zitat Lu P-J, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1–6.CrossRefPubMed Lu P-J, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1–6.CrossRefPubMed
64.
Zurück zum Zitat Elkin Z, Cohen EJ, Goldberg JD, et al. Studying physician knowledge, attitudes, and practices regarding the herpes zoster vaccine to address perceived barriers to vaccination. Cornea. 2013;32(7):976–81.CrossRefPubMed Elkin Z, Cohen EJ, Goldberg JD, et al. Studying physician knowledge, attitudes, and practices regarding the herpes zoster vaccine to address perceived barriers to vaccination. Cornea. 2013;32(7):976–81.CrossRefPubMed
65.
Zurück zum Zitat Javed S, Javed F, Mays RM, et al. Herpes zoster vaccine awareness among people = 50 years of age and its implications on immunization. Dermatol Online J. 2012;18(8):2.PubMed Javed S, Javed F, Mays RM, et al. Herpes zoster vaccine awareness among people = 50 years of age and its implications on immunization. Dermatol Online J. 2012;18(8):2.PubMed
66.
Zurück zum Zitat Hurley LP, Lindley MC, Harpaz R, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152(9):555–60.CrossRefPubMed Hurley LP, Lindley MC, Harpaz R, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152(9):555–60.CrossRefPubMed
67.
Zurück zum Zitat Gerberding J, Yawn BP. Discussing the zoster vaccine: an interview with Julie Gerberding, president of Merck vaccines. Popul Health Manag. 2012;15(6):382–4.CrossRefPubMed Gerberding J, Yawn BP. Discussing the zoster vaccine: an interview with Julie Gerberding, president of Merck vaccines. Popul Health Manag. 2012;15(6):382–4.CrossRefPubMed
69.
Zurück zum Zitat Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2013. Ann Intern Med. 2013;158(3):191–9.CrossRef Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2013. Ann Intern Med. 2013;158(3):191–9.CrossRef
Metadaten
Titel
Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years
verfasst von
Gillian M. Keating
Publikationsdatum
01.07.2013
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 11/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0088-1

Weitere Artikel der Ausgabe 11/2013

Drugs 11/2013 Zur Ausgabe